Meropenem-Vaborbactam vs. Best AvailableTherapy for Carbapenem-ResistantEnterobacteriaceae Infections in TANGO II: PrimaryOutcomes by Site of Infection

Abstract Background Meropenem-vaborbactam (M-V) is a β-lactamase inhibitor combination active against Klebsiella pneumoniaecarbapenemase (KPC)-producing CRE. Few clinical trials of new agents have been conducted in patients with CRE. Methods TANGO II is a randomized, Phase 3, open-label trial in pat...

Full description

Saved in:
Bibliographic Details
Published inOpen forum infectious diseases Vol. 4; no. suppl_1; pp. S536 - S537
Main Authors Wunderink, Richard, Giamarellos-Bourboulis, Evangelos, Rahav, Galia, Mathers, Amy, Bassetti, Matteo, Solomkin, Joseph, Alexander, Elizabeth, Loutit, Jeffrey S, Zhang, Shu, Dudley, Michael N, Kaye, Keith S
Format Journal Article
LanguageEnglish
Published US Oxford University Press 01.10.2017
Online AccessGet full text
ISSN2328-8957
2328-8957
DOI10.1093/ofid/ofx163.1397

Cover

Abstract Abstract Background Meropenem-vaborbactam (M-V) is a β-lactamase inhibitor combination active against Klebsiella pneumoniaecarbapenemase (KPC)-producing CRE. Few clinical trials of new agents have been conducted in patients with CRE. Methods TANGO II is a randomized, Phase 3, open-label trial in patients with infections due to known or suspected CRE, including complicated urinary tract infection (cUTI), acute pyelonephritis (AP), HABP/VABP, bacteremia, or complicated intra-abdominal infection (cIAI). Eligible subjects were randomized 2:1 to monotherapy with M-V or Best Available Therapy (BAT) for 7–14 days. BAT could include (alone or in combination): a carbapenem, aminoglycoside, polymyxin B, colistin, tigecycline or ceftazidime-avibactam (monotherapy only). Enrollment was stratified by infection type and geographic region. Endpoints differed by infection: overall success (clinical cure + microbial eradication) in cUTI/AP, 28-day all-cause mortality in HABP/VABP + bacteremia, and clinical cure in cIAI. It was not powered for inferential statistical testing; results are presented descriptively. Results 72 patients were enrolled: 43 (59.7%) had baseline CRE and comprised the microbiologic CRE modified intent-to-treat population (mCRE-MITT, primary population). In mCRE-MITT, 20 had bacteremia, 15 had cUTI/AP, 5 had HABP/VABP, and 3 had cIAI. Conclusion In this first prospective comparative trial of a β-lactam/β-lactamase inhibitor combination as monotherapy of CRE infections, M-V showed consistent improvement over BAT in efficacy endpoints across infections, and improved safety/tolerability. M-V appears to be an improved treatment option for CRE infections. Disclosures R. Wunderink, The Medicines Company: Consultant and Investigator, Consulting fee and Research grant; G. Rahav, MSD: Consultant, Investigator and Speaker’s Bureau, Consulting fee, Research grant and Speaker honorarium; Pfizer: Consultant, Investigator and Speaker’s Bureau, Consulting fee, Research grant and Speaker honorarium; Astellas: Consultant, Investigator and Speaker’s Bureau, Consulting fee, Research grant and Speaker honorarium; A. Mathers, Accelerate Diagnostics: Consultant, Consulting fee; The Medicines Company: Consultant, Consulting fee; Zavante Therapeutics: Research Contractor, Research support; M. Bassetti, MSD: Consultant, Research Contractor and Speaker’s Bureau, Consulting fee, Research grant and Speaker honorarium; Pfizer: Consultant, Research Contractor and Speaker’s Bureau, Consulting fee, Research grant and Speaker honorarium; Astellas: Consultant and Speaker’s Bureau, Consulting fee and Speaker honorarium; AstraZeneca: Consultant and Speaker’s Bureau, Consulting fee and Speaker honorarium; The Medicines Company: Consultant, Consulting fee; Tetraphase: Consultant and Speaker’s Bureau, Consulting fee and Speaker honorarium; Angelini: Consultant and Speaker’s Bureau, Consulting fee and Speaker honorarium; Basilea: Consultant and Speaker’s Bureau, Consulting fee and Speaker honorarium; Achaogen: Consultant, Consulting fee; Paratek: Consultant, Consulting fee; J. Solomkin, Merck: Consultant, Consulting fee; Tetraphase: Consultant, Consulting fee; 3M: Consultant, Consulting fee; Arsanis: Consultant, Consulting fee; Department of Defense: Research Contractor, Research support; E. Alexander, The Medicines Company: Shareholder, Salary; J. S. Loutit, The Medicine’s Company: Employee and Shareholder, Salary; S. Zhang, The Medicines Company: Shareholder, Salary; M. N. Dudley, The Medicine’s Company: Employee and Shareholder, Salary; K. S. Kaye, Xellia: Consultant, Consulting fee; Merck: Consultant and Grant Investigator, Consulting fee and Research support; The Medicines Company: Consultant and Grant Investigator, Consulting fee and Research support Efficacy by Infection Type M-V (N = 28) n/N’ (%) BAT (N = 15) n/N’ (%) Bacteremia + HABP/VABP All-Cause Mortality, Day 28 4/16 (25.0%) 4/9 (44.4%) cUTI/AP Overall Success at End of Therapy (EOT) 8/11 (72.7%) 2/4 (50%) Overall Success at Test of Cure (TOC, EOT + 7 d) 3/7 (42.9%)* 2/4 (50%) cIAI Clinical Cure at TOC 1/1 (100%) 0/2 (0) *4 M-V subjects were indeterminate/not assessed at TOC. AEs occurred in 84.4% of M-V patients vs. 92% on BAT. M-V was associated with fewer drug-related AEs (24.4% vs. 44%), severe AEs (13.3% vs. 28%), and serious AEs (33.3% vs. 44%) vs. BAT.
AbstractList Abstract Background Meropenem-vaborbactam (M-V) is a β-lactamase inhibitor combination active against Klebsiella pneumoniaecarbapenemase (KPC)-producing CRE. Few clinical trials of new agents have been conducted in patients with CRE. Methods TANGO II is a randomized, Phase 3, open-label trial in patients with infections due to known or suspected CRE, including complicated urinary tract infection (cUTI), acute pyelonephritis (AP), HABP/VABP, bacteremia, or complicated intra-abdominal infection (cIAI). Eligible subjects were randomized 2:1 to monotherapy with M-V or Best Available Therapy (BAT) for 7–14 days. BAT could include (alone or in combination): a carbapenem, aminoglycoside, polymyxin B, colistin, tigecycline or ceftazidime-avibactam (monotherapy only). Enrollment was stratified by infection type and geographic region. Endpoints differed by infection: overall success (clinical cure + microbial eradication) in cUTI/AP, 28-day all-cause mortality in HABP/VABP + bacteremia, and clinical cure in cIAI. It was not powered for inferential statistical testing; results are presented descriptively. Results 72 patients were enrolled: 43 (59.7%) had baseline CRE and comprised the microbiologic CRE modified intent-to-treat population (mCRE-MITT, primary population). In mCRE-MITT, 20 had bacteremia, 15 had cUTI/AP, 5 had HABP/VABP, and 3 had cIAI. Conclusion In this first prospective comparative trial of a β-lactam/β-lactamase inhibitor combination as monotherapy of CRE infections, M-V showed consistent improvement over BAT in efficacy endpoints across infections, and improved safety/tolerability. M-V appears to be an improved treatment option for CRE infections. Disclosures R. Wunderink, The Medicines Company: Consultant and Investigator, Consulting fee and Research grant; G. Rahav, MSD: Consultant, Investigator and Speaker’s Bureau, Consulting fee, Research grant and Speaker honorarium; Pfizer: Consultant, Investigator and Speaker’s Bureau, Consulting fee, Research grant and Speaker honorarium; Astellas: Consultant, Investigator and Speaker’s Bureau, Consulting fee, Research grant and Speaker honorarium; A. Mathers, Accelerate Diagnostics: Consultant, Consulting fee; The Medicines Company: Consultant, Consulting fee; Zavante Therapeutics: Research Contractor, Research support; M. Bassetti, MSD: Consultant, Research Contractor and Speaker’s Bureau, Consulting fee, Research grant and Speaker honorarium; Pfizer: Consultant, Research Contractor and Speaker’s Bureau, Consulting fee, Research grant and Speaker honorarium; Astellas: Consultant and Speaker’s Bureau, Consulting fee and Speaker honorarium; AstraZeneca: Consultant and Speaker’s Bureau, Consulting fee and Speaker honorarium; The Medicines Company: Consultant, Consulting fee; Tetraphase: Consultant and Speaker’s Bureau, Consulting fee and Speaker honorarium; Angelini: Consultant and Speaker’s Bureau, Consulting fee and Speaker honorarium; Basilea: Consultant and Speaker’s Bureau, Consulting fee and Speaker honorarium; Achaogen: Consultant, Consulting fee; Paratek: Consultant, Consulting fee; J. Solomkin, Merck: Consultant, Consulting fee; Tetraphase: Consultant, Consulting fee; 3M: Consultant, Consulting fee; Arsanis: Consultant, Consulting fee; Department of Defense: Research Contractor, Research support; E. Alexander, The Medicines Company: Shareholder, Salary; J. S. Loutit, The Medicine’s Company: Employee and Shareholder, Salary; S. Zhang, The Medicines Company: Shareholder, Salary; M. N. Dudley, The Medicine’s Company: Employee and Shareholder, Salary; K. S. Kaye, Xellia: Consultant, Consulting fee; Merck: Consultant and Grant Investigator, Consulting fee and Research support; The Medicines Company: Consultant and Grant Investigator, Consulting fee and Research support Efficacy by Infection Type M-V (N = 28) n/N’ (%) BAT (N = 15) n/N’ (%) Bacteremia + HABP/VABP All-Cause Mortality, Day 28 4/16 (25.0%) 4/9 (44.4%) cUTI/AP Overall Success at End of Therapy (EOT) 8/11 (72.7%) 2/4 (50%) Overall Success at Test of Cure (TOC, EOT + 7 d) 3/7 (42.9%)* 2/4 (50%) cIAI Clinical Cure at TOC 1/1 (100%) 0/2 (0) *4 M-V subjects were indeterminate/not assessed at TOC. AEs occurred in 84.4% of M-V patients vs. 92% on BAT. M-V was associated with fewer drug-related AEs (24.4% vs. 44%), severe AEs (13.3% vs. 28%), and serious AEs (33.3% vs. 44%) vs. BAT.
Author Wunderink, Richard
Giamarellos-Bourboulis, Evangelos
Loutit, Jeffrey S
Alexander, Elizabeth
Solomkin, Joseph
Rahav, Galia
Kaye, Keith S
Dudley, Michael N
Mathers, Amy
Bassetti, Matteo
Zhang, Shu
Author_xml – sequence: 1
  givenname: Richard
  surname: Wunderink
  fullname: Wunderink, Richard
  organization: Northwestern University Feinberg School of Medicine, Chicago, Illinois
– sequence: 2
  givenname: Evangelos
  surname: Giamarellos-Bourboulis
  fullname: Giamarellos-Bourboulis, Evangelos
  organization: Athens Medical School, Athens, Greece
– sequence: 3
  givenname: Galia
  surname: Rahav
  fullname: Rahav, Galia
  organization: Sheba Medical Center, Tel Hashomer, Israel
– sequence: 4
  givenname: Amy
  surname: Mathers
  fullname: Mathers, Amy
  organization: University of Virginia Health System, Charlottesville, Virginia
– sequence: 5
  givenname: Matteo
  surname: Bassetti
  fullname: Bassetti, Matteo
  organization: San Martino Hospital, Genova, Italy
– sequence: 6
  givenname: Joseph
  surname: Solomkin
  fullname: Solomkin, Joseph
  organization: University of Cincinnati, Cincinnati, Ohio
– sequence: 7
  givenname: Elizabeth
  surname: Alexander
  fullname: Alexander, Elizabeth
  organization: The Medicines Company, Parsippany, New Jersey
– sequence: 8
  givenname: Jeffrey S
  surname: Loutit
  fullname: Loutit, Jeffrey S
  organization: The Medicines Company, San Diego, California
– sequence: 9
  givenname: Shu
  surname: Zhang
  fullname: Zhang, Shu
  organization: The Medicines Company, Parsippany, New Jersey
– sequence: 10
  givenname: Michael N
  surname: Dudley
  fullname: Dudley, Michael N
  organization: The Medicines Company, San Diego, California
– sequence: 11
  givenname: Keith S
  surname: Kaye
  fullname: Kaye, Keith S
  organization: University of Michigan Medical School, Ann Arbor, Michigan
BookMark eNqNkE1v1DAQQC1UJNrSO0ffqyzjOF_mtl2VslJhEd1yjSbesWqUtSPbW9hfwt8lUZBAPUAvM6PRvLHnnbET5x0x9kbAQoCSb72xuzH8EJVcCKnqF-w0l3mTNaqsT_6qX7GLGL8BgBBQQq1O2c-PFPxAjvbZV-x86FAn3PPHuOBXFBNfPqLtsetp-0ABhyM3PvAVjnMz9IWijQldunZp3DThFCxqQuJrZ0gn613k1vHt8tPNhq_X7_jnYPcYjptD0n5PkXdHfmcTcW_-IK_ZS4N9pIvf-Zzdv7_erj5kt5ub9Wp5m2lRVXVW6k6CQqAGS4n5risMlnWJTaFUoRoYGxXtQBmAstBVXknYNUVeooFCVqaW50zMew9uwON37Pt2mL_XCmgnue0kt53ltpPckYGZ0cHHGMg8B6meINomnA5NYRT8L_ByBv1h-P8zvwDo06QE
CitedBy_id crossref_primary_10_1128_AAC_01551_18
crossref_primary_10_2147_IDR_S187360
crossref_primary_10_1007_s40265_019_1054_3
ContentType Journal Article
Copyright The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2017
Copyright_xml – notice: The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2017
DBID TOX
AAYXX
CITATION
ADTOC
UNPAY
DOI 10.1093/ofid/ofx163.1397
DatabaseName Oxford Journals Open Access Collection
CrossRef
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle CrossRef
DatabaseTitleList
Database_xml – sequence: 1
  dbid: TOX
  name: Oxford Journals Open Access (Activated by CARLI)
  url: https://academic.oup.com/journals/
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate ID Week 2017 Abstracts
EISSN 2328-8957
EndPage S537
ExternalDocumentID 10.1093/ofid/ofx163.1397
10_1093_ofid_ofx163_1397
GroupedDBID 0R~
53G
5VS
AAFWJ
AAMVS
AAPPN
AAPXW
AAVAP
ABDBF
ABPTD
ABXVV
ACGFS
ADBBV
ADHZD
ADPDF
ADRAZ
AENZO
AFPKN
AFULF
ALMA_UNASSIGNED_HOLDINGS
ALUQC
AOIJS
BAWUL
BAYMD
BCNDV
BTTYL
CIDKT
DIK
EBS
EJD
GROUPED_DOAJ
H13
HYE
IAO
KQ8
KSI
M48
M~E
O9-
OAWHX
OJQWA
OK1
OVD
OVEED
PEELM
ROL
ROX
RPM
TEORI
TJX
TOX
7X7
8C1
8FI
8FJ
AAYXX
ABEJV
ABGNP
ABUWG
ACUHS
AFKRA
AMNDL
BENPR
CCPQU
CITATION
FYUFA
HMCUK
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PUEGO
UKHRP
ADTOC
IHR
ITC
UNPAY
ID FETCH-LOGICAL-c1667-5cb309a0e8a53a2db4fa575a84994980db46ed09f0054c62630d8425af0436f73
IEDL.DBID M48
ISSN 2328-8957
IngestDate Tue Aug 19 19:32:58 EDT 2025
Thu Apr 24 23:03:38 EDT 2025
Wed Oct 01 04:14:40 EDT 2025
Wed Aug 28 03:26:17 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue suppl_1
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c1667-5cb309a0e8a53a2db4fa575a84994980db46ed09f0054c62630d8425af0436f73
OpenAccessLink https://dx.doi.org/10.1093/ofid/ofx163.1397
ParticipantIDs unpaywall_primary_10_1093_ofid_ofx163_1397
crossref_primary_10_1093_ofid_ofx163_1397
crossref_citationtrail_10_1093_ofid_ofx163_1397
oup_primary_10_1093_ofid_ofx163_1397
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2017-10-01
PublicationDateYYYYMMDD 2017-10-01
PublicationDate_xml – month: 10
  year: 2017
  text: 2017-10-01
  day: 01
PublicationDecade 2010
PublicationPlace US
PublicationPlace_xml – name: US
PublicationTitle Open forum infectious diseases
PublicationYear 2017
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
SSID ssj0001105079
Score 2.0329378
Snippet Abstract Background Meropenem-vaborbactam (M-V) is a β-lactamase inhibitor combination active against Klebsiella pneumoniaecarbapenemase (KPC)-producing CRE....
SourceID unpaywall
crossref
oup
SourceType Open Access Repository
Enrichment Source
Index Database
Publisher
StartPage S536
Title Meropenem-Vaborbactam vs. Best AvailableTherapy for Carbapenem-ResistantEnterobacteriaceae Infections in TANGO II: PrimaryOutcomes by Site of Infection
URI https://academic.oup.com/ofid/article-pdf/4/suppl_1/S536/20430390/ofx163.1397.pdf
UnpaywallVersion publishedVersion
Volume 4
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Colorado Digital library
  customDbUrl:
  eissn: 2328-8957
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001105079
  issn: 2328-8957
  databaseCode: KQ8
  dateStart: 20140101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2328-8957
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001105079
  issn: 2328-8957
  databaseCode: DOA
  dateStart: 20140101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVEBS
  databaseName: Academic Search Ultimate
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 2328-8957
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001105079
  issn: 2328-8957
  databaseCode: ABDBF
  dateStart: 20140901
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 2328-8957
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001105079
  issn: 2328-8957
  databaseCode: DIK
  dateStart: 20140101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2328-8957
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001105079
  issn: 2328-8957
  databaseCode: M~E
  dateStart: 20140101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2328-8957
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001105079
  issn: 2328-8957
  databaseCode: RPM
  dateStart: 20140101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVOVD
  databaseName: Journals@Ovid LWW All Open Access Journal Collection Rolling
  customDbUrl:
  eissn: 2328-8957
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001105079
  issn: 2328-8957
  databaseCode: OVEED
  dateStart: 20140301
  isFulltext: true
  titleUrlDefault: http://ovidsp.ovid.com/
  providerName: Ovid
– providerCode: PRVASL
  databaseName: Oxford Journals Open Access (Activated by CARLI)
  customDbUrl:
  eissn: 2328-8957
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001105079
  issn: 2328-8957
  databaseCode: TOX
  dateStart: 20140101
  isFulltext: true
  titleUrlDefault: https://academic.oup.com/journals/
  providerName: Oxford University Press
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 2328-8957
  dateEnd: 20241001
  omitProxy: true
  ssIdentifier: ssj0001105079
  issn: 2328-8957
  databaseCode: 7X7
  dateStart: 20140401
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 2328-8957
  dateEnd: 20241001
  omitProxy: true
  ssIdentifier: ssj0001105079
  issn: 2328-8957
  databaseCode: BENPR
  dateStart: 20140401
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Public Health Database
  customDbUrl:
  eissn: 2328-8957
  dateEnd: 20241001
  omitProxy: true
  ssIdentifier: ssj0001105079
  issn: 2328-8957
  databaseCode: 8C1
  dateStart: 20140401
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/publichealth
  providerName: ProQuest
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 2328-8957
  dateEnd: 20250831
  omitProxy: true
  ssIdentifier: ssj0001105079
  issn: 2328-8957
  databaseCode: M48
  dateStart: 20141201
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lj9owELa6IHV7qfpU2XaRD3tppbBpyItK1QoQ26USD1GouEVjZyIhhcCSQOGX9O92HLu7rYT6uPiQjBPFnzP-7PF8ZuwiIc_oBYjk_QAs1_PAEuiAFWNg01wMpVNmpQ2G_s3M_Tz35vfp0aYB86NTO3We1GyTNva3hyv64T8aMaRLQiGmYk_UoqEIzQmr0rjkqD4-MGS_XHEhKmGX4nvEIkIrbHmBiVsee8hv45TOfTvdZms4fIM0_WUIun7CHhvuyNsa7KfsAWbP2MOBiY4_Z98HqJbWM1xaXxW2AmQBS77LG7xDzp-3d7BIVarUVEsJcCKsvKsCDrrSBHPFJrOi3CmwElrIGSQC8r7ZtJXlfJHxaXv4acT7_Q98rNUqRtuCui7mXBz4F2KxfJXcV3nBZte9affGMgcvWPK9T47Tk6Jpt8DGELwmOLFwEyBaByFNj9xWaNMFH2O7lSjCJ5WejR2rcB4kStA-CZovWSVbZfiKcekIRAmh8GXsgi9Duo8OkSYXpEgCt8YufzZzJI0quTocI410dLwZKWAiDUykgKmxt3c11vob_2B7Qcj9g9m7O2j_anz2H-9_zR45igaUm__esEqx2eI5kZhC1Fm10xuOJ_VyEaBe9lQqp6P5DyqY9fc
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Meropenem-Vaborbactam+vs.+Best+AvailableTherapy+for+Carbapenem-ResistantEnterobacteriaceae+Infections+in+TANGO+II%3A+PrimaryOutcomes+by+Site+of+Infection&rft.jtitle=Open+forum+infectious+diseases&rft.au=Wunderink%2C+Richard&rft.au=Giamarellos-Bourboulis%2C+Evangelos&rft.au=Rahav%2C+Galia&rft.au=Mathers%2C+Amy&rft.pub=Oxford+University+Press&rft.eissn=2328-8957&rft.volume=4&rft.issue=suppl_1&rft.spage=S536&rft.epage=S537&rft_id=info:doi/10.1093%2Fofid%2Fofx163.1397&rft.externalDocID=10.1093%2Fofid%2Fofx163.1397
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2328-8957&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2328-8957&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2328-8957&client=summon